🇺🇸 Atorvastatin (Lipitor) in United States

55 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 10 reports (18.18%)
  2. Nausea — 7 reports (12.73%)
  3. Pneumonia — 6 reports (10.91%)
  4. Acute Kidney Injury — 5 reports (9.09%)
  5. Atrial Fibrillation — 5 reports (9.09%)
  6. Diarrhoea — 5 reports (9.09%)
  7. Fatigue — 5 reports (9.09%)
  8. Acute Respiratory Failure — 4 reports (7.27%)
  9. Chest Pain — 4 reports (7.27%)
  10. Chronic Kidney Disease — 4 reports (7.27%)

Source database →

Other Cardiovascular approved in United States

Frequently asked questions

Is Atorvastatin (Lipitor) approved in United States?

Atorvastatin (Lipitor) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Atorvastatin (Lipitor) in United States?

University of Chicago is the originator. The local marketing authorisation holder may differ — check the official source linked above.